Navigation Links
Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia
Date:3/3/2009

- 31% COMPLETE RESPONSE RATE

- MEDIAN SURVIVAL OF 10.5 MONTHS IN COMPLETE RESPONDERS

- FINAL DATA TARGETED FOR 2009 ASH ANNUAL MEETING

SOUTH SAN FRANCISCO, Calif., March 3 /PRNewswire-FirstCall/ -- Hana Biosciences (Nasdaq: HNAB) today announced new positive preliminary efficacy results from a planned interim analysis of the ongoing pivotal rALLy clinical trial evaluating Marqibo(R) (vincristine sulfate liposomes injection) for the treatment of adult acute lymphoblastic leukemia (ALL) in second relapse. The analysis revealed that nine patients, or 31 percent, of the first 29 evaluable subjects achieved a complete response (CR) or CR without full blood count recovery (CRi). The estimated median overall survival (OS) in responders was 10.5 months compared to 5.1 months in non-responders at the time of the data cutoff. Because six of the nine CRs were still alive at that time, the median OS in this group may prove to be longer.

Since the outset of the rALLy trial, the target response rate for the study has been 16% complete responses (i.e., CR or CRi), which equates to nine or more out of the target evaluable population of 56 subjects. Completion of rALLy will satisfy the Company's need for greater than 100 Marqibo-treated adult ALL patients and catalyze the completion and submission of a New Drug Application for accelerated approval.

"We are strongly encouraged by these excellent preliminary results that show we have already met our overall study goal with regards to the number of complete responses in the first 29 patients, and importantly corroborate previously reported Marqibo activity in past clinical trials," said Steven R. Deitcher, M.D., president and chief executive officer. "These data fully support our plans to submit a New Drug Application for accelerated approval of
'/>"/>

SOURCE Hana Biosciences
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
2. Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
3. YM BioSciences Announces Milestone Payment For Approval Of Nimotuzumab In The Philippines And Indonesia
4. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
5. Chipscreen Biosciences and HUYA Bioscience Intl Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer
6. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
7. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
8. Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
9. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
10. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
11. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 AARP Foundation today announced it has ... adults suffering from the severe cold weather that has ... are committed to helping those in need; so to ... will match dollar-for-dollar contributions up to $250,000, which could ... will be administered through AARP Foundation. ...
(Date:1/15/2014)... Texas , Jan. 15, 2014  Humberto C. ... Dermatology Achievement Award" from the Journal of Drugs ... Aesthetic & Clinical Conference (ODAC). The event is January 17-20, ... Florida . The ODAC ... on the practice of dermatology for clinical and aesthetic ...
(Date:1/15/2014)... -- MultiCell Technologies, Inc. (OTC Bulletin Board: ... concerning composition of matter, biological targets, mechanism of action, ... This patent application describes a novel ... (VSRNAs) which interfere with the basic homeostatic cellular processes ... than 10 bps, yet are surprisingly capable in their ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... (NASDAQ: PRXL ) announced today that it will ... FL.  James Winschel, Sr. Vice President and Chief Financial Officer ... on Tuesday, March 13, 2012. A live webcast ... section of PAREXEL,s website at www.PAREXEL.com in ...
... Angeion Corporation (NASDAQ: ANGN ) today announced that ... Board of Directors, effective March 1, 2012. ... Choice in Health Care at the Altarum Institute. She also ... School of Nursing at Indiana University/Purdue University at Indianapolis and ...
Cached Medicine Technology:PAREXEL International to Present at Barclays Capital Healthcare Conference 2Wendy D. Lynch, Ph.D., Joins Angeion's Board of Directors 2Wendy D. Lynch, Ph.D., Joins Angeion's Board of Directors 3Wendy D. Lynch, Ph.D., Joins Angeion's Board of Directors 4
(Date:4/14/2014)... In a UT Dallas study involving serious youth offenders, the ... for the next seven years: "How long do you think ... the future encourages offending over time., Author Dr. Alex Piquero ... long life ahead of them offend at very high rates ... going to die much later in life offend much less., ...
(Date:4/14/2014)... SAN FRANCISCO, Calif.--True North Therapeutics, Inc., announced today ... prevents the destruction of human red blood cells ... type of autoimmune hemolytic anemia (AIHA). The article ... C1s, prevents complement activation induced by cold agglutinin ... journal Blood earlier this month. TNT003 ...
(Date:4/14/2014)... world, many people live and work in dim and ... And as the global population continues to rise and ... spread. , To alleviate the problem, Egyptian researchers ... onto narrow streets and alleyways. The panel is mounted ... angle, where it spreads sunlight onto the street below. ...
(Date:4/14/2014)... professor of chemical engineering at Virginia Tech , ... analyze living cells. The long-term goal is to gain ... In his lab , Lu and his students ... events inside cells. These devices promote high sensitivity and ... cells. , Based on their record of achievements, the ...
(Date:4/14/2014)... Australia. Drug discovery company Proteomics International has completed ... companion diagnostic (CDx) test with the validation of ... team authenticated the panel of biomarkers after taking ... biomarkers were validated at high stringency using the ... spectrometry data was then cross-validated using immunoassays in ...
Breaking Medicine News(10 mins):Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Ex vivo efficacy of C1s antibody as Complement inhibitor in cold agglutinin disease 2Health News:Let the sun shine in: Redirecting sunlight to urban alleyways 2Health News:Efficient analysis of small quantity of cells improves chances to understand disease 2
... (HealthDay News) -- The total economic cost of overweight and obesity ... cost in Canada is about $30 billion a year, a new ... States and Canada is the result of: increased need for medical ... of death ($49 billion); loss of productivity due to disability of ...
... whether interstitial brachytherapy has advantages compared to other therapy options ... provide proof in this respect. This is the result of ... in Health Care (IQWiG) on 11 January 2011. In this ... research already completed in 2007. However, it was shown that ...
... January 2011: With its spotlight theme of ,Controversial ... Society of Cardiology (ESC) Congress promises lively discussions and ... as the world,s premier cardiovascular conference and regularly attracts ... through its doors. It will be held this ...
... (MDCT) provides an efficient, effective way to analyze wounds from ... and in the March issue of Radiology . ... improve patient care and aid in both military and civilian ... D.O., M.P.H., from the Uniformed Services University in Bethesda, Md. ...
... that closely mirror some of the key properties of red ... of synthetic blood. The new discovery outlined in ... Proceedings of the National Academy of Sciences during ... to more effective treatments for life threatening medical conditions such ...
... , MONDAY, Jan. 10 (HealthDay News) -- The ... how to create a vaccine that can protect people against ... that people who were infected with the H1N1 virus and ... against a wide variety of flu strains. The virus ...
Cached Medicine News:Health News:Cost of Obesity Approaching $300 Billion a Year 2Health News:Benefit of brachytherapy in patients with early-stage prostate cancer is still unclear 2Health News:Benefit of brachytherapy in patients with early-stage prostate cancer is still unclear 3Health News:Benefit of brachytherapy in patients with early-stage prostate cancer is still unclear 4Health News:Countdown to Paris and ESC Congress 2011 2Health News:Countdown to Paris and ESC Congress 2011 3Health News:CT helps identify bullet trajectories 2Health News:UNC researchers inch closer to unlocking potential of synthetic blood 2Health News:UNC researchers inch closer to unlocking potential of synthetic blood 3Health News:People Who Recovered From H1N1 Offer Clues to Better Vaccine 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: